DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicants arguments and amendments filed on 6/25/2026 have been entered.
Claims 38, 49, 52 and 53 have been amended.
In view of Applicants amendments the 112(b) rejection is withdrawn.
In view of Applicants amendments the 102 rejection has been amended.
Claims 38, 47, 49, 52, 53 and 57 are examined in the instant application.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 38, 47, 49, 52, 53 and 57 remain rejected under 35 U.S.C. 102(a)(1) as being anticipated by Keravala et al. (WO 2020/014523, published 1/16/2020) for reasons of record in the Non-Final Office Action mailed on 4/1/2026 (and repeated as amended below).
Regarding claims 38 and 49, Keravala et al. teach pharmaceutical composition for treating Danon disease comprising an AAV comprising CAG promoter and a nucleotide sequence encoding a LAMP2B protein, wherein the therapeutic amount about 1 x 1013 vg/kg to about 6.7 x 1013 vg/kg (see Abstract, Fig. 1A, reproduced below, pg. 1 lines 26-28, pg. 32 line 7 bridge pg. 33 line 2 and pg. 35 lines 5-16).
PNG
media_image1.png
276
783
media_image1.png
Greyscale
Regarding claim 47 and SEQ ID NO: 1, Keravala teaches that their encoded LAMP2B protein (SEQ ID NO: 2) is 100% identical to instantly recited SEQ ID NO: 1.
PNG
media_image2.png
57
565
media_image2.png
Greyscale
Regarding claim 52, Keravala teaches:
SEQ ID NO: 22 which is 100% identical instantly recited SEQ ID NO: 22
PNG
media_image3.png
49
562
media_image3.png
Greyscale
SEQ ID NO: 3 which is 100% identical to instantly recited SEQ ID NO: 3
PNG
media_image4.png
58
562
media_image4.png
Greyscale
SEQ ID NO: 75 which is 100% identical to instantly recited SEQ ID NO: 27
PNG
media_image5.png
51
566
media_image5.png
Greyscale
SEQ ID NO: 42 which is 100% identical to instantly recited SEQ ID NO: 7
PNG
media_image6.png
52
564
media_image6.png
Greyscale
Regarding claim 53, Keravala teaches:
SEQ ID NO: 11 which is 100% identical to instantly recited SEQ ID NO: 11
PNG
media_image7.png
60
567
media_image7.png
Greyscale
SEQ ID NO: 12, which is 100% identical to instantly recited SEQ ID NO: 12
PNG
media_image8.png
58
569
media_image8.png
Greyscale
Regarding claim 57, with respect to the term kit, the claimed kit is not accorded any patentable weight, as it is directed to a composition comprising the pharmaceutical composition of the invention. Regarding instructions, the inclusion of instructions is not considered to provide a patentable limitation on the claims because the instructions merely represent a statement of intended use in the form of instructions in a kit. See In re Ngai, 367 F.3d 1336, 70 U.S.P.Q.2d 1862 (Fed. Cir. 2004) (holding that an inventor could not patent known kits by simply attaching new set of instructions to that product).
Thus, the teachings of Keravala clearly anticipate the invention of claims 38, 47, 49, 52, 53 and 57.
Response to Arguments
Applicants argue that Keravala does not teach the therapeutic dose range in amended claim 38. This argument is not found persuasive as Kervala teaches the amended dose range as set forth above. Thus for the reasons above and of record the rejection is maintained.
Conclusion
No claims are allowed.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID A MONTANARI whose telephone number is (571)272-3108. The examiner can normally be reached M-Tr 8-6.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
DAVID A. MONTANARI
Examiner
Art Unit 1632
/ANOOP K SINGH/Primary Examiner, Art Unit 1632